Recently, the connection between type 2 diabetes and MASLD has gained significant attention, with evidence confirming that diabetes medications, including thiazolidinediones, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), are effective in treating fatty liver [9-11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.